Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Aged <65 Versus >65 Years

摘要

atients younger than 65 years are at increased risk for CINV.1'2 Patients ages 65 years and older are at greater risk for CINV-related complications, including dehydration, impaired renal function, and abnormal blood pressure. The efficacy of rolapitant (180 mg) administered as a single dose in combination with a 5-HT_3 receptor antagonist plus dexamethasone has been demonstrated in placebo-controlled, randomized phase 3 trials in patients receiving HEC or MEC. In these pivotal, phase 3 trials, patients recorded emetic episodes and use of rescue medication in diaries for approximately 120 hours following administration of chemotherapy. Each trial had a primary endpoint of CR, defined as no emesis and no use of rescue medication during the delayed phase.